Actively Recruiting
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Led by AHS Cancer Control Alberta · Updated on 2025-05-14
1534
Participants Needed
1
Research Sites
1377 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A \[68\]Ga-HA-DOTATATE PET/CT or PET/MRI scan is a nuclear medicine test used to create pictures of the whole body that will show where somatostatin receptors are found, including on tumours. Somatostatin receptors are found on most neuroendocrine tumours (NETs), and some other types of tumours. Currently at the Cross Cancer Institute, most patients with suspected somatostatin positive tumours (e.g. NETs) have an In-111 Octreotide (Octreoscan™) scan. A scientific study has shown that a scan with a similar product (\[68\]Ga-DOTATATE) is more accurate than an Octreoscan™. This study will look at \[68\]Ga-HA-DOTATATE, a product virtually identical to \[68\]Ga-DOTATATE. The purpose of this study is to: 1) demonstrate the safety of \[68\]Ga-HA-DOTATATE; and 2) confirm that \[68\]Ga-HA-DOTATATE PET/CT or PET/MRI is effective at diagnosing somatostatin positive tumours.
CONDITIONS
Official Title
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Known or suspected somatostatin receptor positive tumor including types such as GNET, PNET, pulmonary NET, pheochromocytoma, paraganglioma, medullary thyroid cancer, and medulloblastoma
- Standard CT scan obtained within 6 months before enrollment
- Eastern Cooperative Oncology Group (ECOG) Performance Scale Score of 3 or less within 2 weeks before enrollment
- At least 14 years of age
- Able and willing to follow instructions and comply with the protocol
- Able to provide written informed consent before participating in the study
You will not qualify if you...
- Unable to lie still for the entire imaging time (e.g., due to cough or severe arthritis)
- Unable to complete required imaging exams due to claustrophobia, radiation phobia, or other reasons
- Any serious medical condition or illness that may interfere with study participation or results
- Weight exceeding the PET/CT or PET/MR scanner limit
- Pregnant
- Allergic reaction to DOTATATE or somatostatin analogues
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
Research Team
N
NET Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here